Sero-prevalence of Hepatitis B virus and plasmodium co-infection profile among patients in Wukari and Environs, North East Nigeria

Hepatitis B virus and plasmodium co-infection is of an increase in developing countries as a result of lack of proper diagnosis leading to increased morbidity. This study was to determine the sero-prevalence of Hepatitis B Virus and Plasmodium co-infection profile among patients in Wukari and environs. Seventy (70) subjects’ with the age range of between 0 to 80 years participated and standard microbiological techniques were observed in this study. The results obtained showed 34 (48.6%) were males and 36 (51.4%) were females. Four (5.7%) participants were sero-positive for HBsAg. HBsAb, HBcAb, HBeAg and HBeAb while 66 were not detected positive. The Male with 5.9% participants were sero-positive while 5.6% of the female participants were sero-positive. 20 (28.6%) of the participants were sero-positive for malaria. This comprises of 7 males and 13 females. 20.6% of the males were sero-positive while 36.1% of the females were sero-positive. The distribution of parasitaemia by gender across the participants showed that 24 (34.3%) had plasmodium parasitaemia, out of which 9 were males and 15 were females. 26.5% of the males and 41.7% of the females had plasmodium parasitaemia. There was no co-infection of Hepatitis B virus and malaria, despite both having prevalence of 5.7% and 34.3% respectively. The research on its own has shown that in order to reduce HBV and plasmodium co-infection, mass immunization of adults and antiviral drugs should be provided for those that are infected, while HBV and plasmodium co-infections screening programs should be instituted in all levels of institutions in the country to reduce the prevalence rate and level of transmission of the hepatitis virus. This study also has added to the puddle of knowledge already available in this area of research.

Different Infection Profiles and Antimicrobial Resistance Patterns Between Burn ICU and Common Wards

Infection is the leading cause of complications and deaths after burns. However, the difference in infection patterns between the burn intensive care unit (BICU) and burn common wards (BCW) have not been clearly investigated. The present study aimed to compare the infection profile, antimicrobial resistance, and their changing patterns in burn patients in BICU and BCW. Clinical samples were analyzed between January 1, 2011, and December 31, 2019, in the Institute of Burn Research in Southwest China. The patient information, pathogen distribution, sources, and antimicrobial resistance were retrospectively collected. A total of 3457 and 4219 strains were detected in BICU and BCW, respectively. Wound secretions accounted for 86.6% and 44.9% in BCW and BICU, respectively. Compared with samples in BCW, samples in BICU had more fungi (11.8% vs. 8.1%), more Gram-negative bacteria (60.0% vs. 50.8%), and less Gram-positive bacteria (28.2% vs. 41.1%). Acinetobacter baumannii were the most common pathogen in BICU, compared with Staphylococcus aureus in BCW. S. aureus was the most frequent pathogen in wound secretions and tissues from both BICU and BCW. However, A. baumannii were the first in blood, sputum, and catheter samples from BICU. Overall, the multidrug-resistance (MDR) rate was higher in BICU than in BCW. However, the gap between BICU and BCW gradually shortened from 2011 to 2019. The prevalence of MDR A. baumannii and Klebsiella pneumonia significantly increased, especially in BCW. Furthermore, Carbapenem resistance among K. pneumoniae significantly increased in BICU (4.5% in 2011 vs. 40% in 2019) and BCW (0 in 2011 vs. 40% in 2019). However, the percentage of MDR P. aeruginosa sharply dropped from 85.7% to 24.5% in BICU. The incidence of MRSA was significantly higher in BICU than in BCW (94.2% vs. 71.0%) and stayed at a high level in BICU (89.5% to 96.3%). C. tropicalis and C. albicans were the two most frequent fungi. No resistance to Amphotericin B was detected. Our study shows that the infection profile is different between BICU and BCW, and multidrug resistance is more serious in BICU than BCW. Therefore, different infection-control strategies should be emphasized in different burn populations.

SARS-CoV-2 infected host cell proteomics reveal potential therapy targets

A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), for which, at this point, over 80,000 cases resulting in over 2,500 deaths have been reported in over 40 countries. SARS-CoV-2 shows some similarities to other coronaviruses. However, treatment options and a cellular understanding of SARS-CoV-2 infection are lacking. Here we identify the host cell pathways modulated by SARS-CoV-19 infection and reveal that drugs targeting pathways prevent viral replication in human cells. We established a human cell culture model for infection with SARS-CoV-2 clinical isolate. Employing this system, we determined the SARS-CoV-2 infection profile by translatome and proteome proteomics at different times after infection.These analyses revealed that SARS-CoV-2 reshapes central cellular pathways, such as translation, splicing, carbon metabolism and nucleic acid metabolism. Small molecule inhibitors targeting these pathways were tested in cellular infection assays and prevented viral replication. Our results reveal the cellular infection profile of SARS-CoV-2 and led to the identification of drugs inhibiting viral replication. We anticipate our results to guide efforts to develop therapy options for COVID-19.Authors Denisa Bojkova, Kevin Klann, and Benjamin Koch contributed equally to this workData associated with the preprint has been made available on the authors' website.